Adam Nabeebaccus1, Sean Zheng1, Ajay M Shah2. 1. Cardiovascular Division, King's College London British Heart Foundation Centre of Research Excellence, London, UK. 2. Cardiovascular Division, King's College London British Heart Foundation Centre of Research Excellence, London, UK ajay.shah@kcl.ac.uk.
Abstract
INTRODUCTION/ BACKGROUND: Heart failure is a major cause of cardiovascular morbidity and mortality. This review covers current heart failure treatment guidelines, emerging therapies that are undergoing clinical trial, and potential new therapeutic targets arising from basic science advances. SOURCES OF DATA: A non-systematic search of MEDLINE was carried out. International guidelines and relevant reviews were searched for additional articles. AREAS OF AGREEMENT: Angiotensin-converting enzyme inhibitors and beta-blockers are first line treatments for chronic heart failure with reduced left ventricular function. AREAS OF CONTROVERSY: Treatment strategies to improve mortality in heart failure with preserved left ventricular function are unclear. GROWING POINTS: Many novel therapies are being tested for clinical efficacy in heart failure, including those that target natriuretic peptides and myosin activators. A large number of completely novel targets are also emerging from laboratory-based research. Better understanding of pathophysiological mechanisms driving heart failure in different settings (e.g. hypertension, post-myocardial infarction, metabolic dysfunction) may allow for targeted therapies. AREAS TIMELY FOR DEVELOPING RESEARCH: Therapeutic targets directed towards modifying the extracellular environment, angiogenesis, cell viability, contractile function and microRNA-based therapies.
INTRODUCTION/ BACKGROUND: Heart failure is a major cause of cardiovascular morbidity and mortality. This review covers current heart failure treatment guidelines, emerging therapies that are undergoing clinical trial, and potential new therapeutic targets arising from basic science advances. SOURCES OF DATA: A non-systematic search of MEDLINE was carried out. International guidelines and relevant reviews were searched for additional articles. AREAS OF AGREEMENT: Angiotensin-converting enzyme inhibitors and beta-blockers are first line treatments for chronic heart failure with reduced left ventricular function. AREAS OF CONTROVERSY: Treatment strategies to improve mortality in heart failure with preserved left ventricular function are unclear. GROWING POINTS: Many novel therapies are being tested for clinical efficacy in heart failure, including those that target natriuretic peptides and myosin activators. A large number of completely novel targets are also emerging from laboratory-based research. Better understanding of pathophysiological mechanisms driving heart failure in different settings (e.g. hypertension, post-myocardial infarction, metabolic dysfunction) may allow for targeted therapies. AREAS TIMELY FOR DEVELOPING RESEARCH: Therapeutic targets directed towards modifying the extracellular environment, angiogenesis, cell viability, contractile function and microRNA-based therapies.
Authors: John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana R Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas M Severin; Marco Metra Journal: Lancet Date: 2012-11-07 Impact factor: 79.321
Authors: Bianca C Bernardo; Xiao-Ming Gao; Catherine E Winbanks; Esther J H Boey; Yow Keat Tham; Helen Kiriazis; Paul Gregorevic; Susanna Obad; Sakari Kauppinen; Xiao-Jun Du; Ruby C Y Lin; Julie R McMullen Journal: Proc Natl Acad Sci U S A Date: 2012-10-09 Impact factor: 11.205
Authors: Guido Tarone; Jean-Luc Balligand; Johann Bauersachs; Angela Clerk; Leon De Windt; Stephane Heymans; Denise Hilfiker-Kleiner; Emilio Hirsch; Guido Iaccarino; Ralph Knöll; Adelino F Leite-Moreira; André P Lourenço; Manuel Mayr; Thomas Thum; Carlo G Tocchetti Journal: Eur J Heart Fail Date: 2014-03-17 Impact factor: 15.534
Authors: Barry Greenberg; Javed Butler; G Michael Felker; Piotr Ponikowski; Adriaan A Voors; Akshay S Desai; Denise Barnard; Alain Bouchard; Brian Jaski; Alexander R Lyon; Janice M Pogoda; Jeffrey J Rudy; Krisztina M Zsebo Journal: Lancet Date: 2016-01-21 Impact factor: 79.321
Authors: María Tamayo; Laura Martín-Nunes; Almudena Val-Blasco; Maria José G M-Piedras; José Alberto Navarro-García; Eduardo Lage; Patricia Prieto; Gema Ruiz-Hurtado; María Fernández-Velasco; Carmen Delgado Journal: Br J Pharmacol Date: 2020-04-22 Impact factor: 8.739
Authors: Sean Lee Zheng; Fiona T Chan; Adam A Nabeebaccus; Ajay M Shah; Theresa McDonagh; Darlington O Okonko; Salma Ayis Journal: Heart Date: 2017-08-05 Impact factor: 5.994
Authors: Hui-Fang Song; Sheng He; Shu-Hong Li; Jun Wu; Wenjuan Yin; Zhengbo Shao; Guo-Qing Du; Jie Wu; Jiao Li; Richard D Weisel; Subodh Verma; Jun Xie; Ren-Ke Li Journal: J Cell Mol Med Date: 2020-07-06 Impact factor: 5.310
Authors: Matthew Dukinfield; Eleni Maniati; Louise E Reynolds; Aisah Aubdool; Reshma S Baliga; Gabriela D'Amico; Oscar Maiques; Jun Wang; Kenneth C Bedi; Kenneth B Margulies; Victoria Sanz-Moreno; Adrian Hobbs; Kairbaan Hodivala-Dilke Journal: J Pathol Date: 2019-10-30 Impact factor: 7.996